Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Queensland Health
Argus Health
Cipla
US Department of Justice
Johnson and Johnson

Generated: August 23, 2019

DrugPatentWatch Database Preview

Litigation Details for Abbott Laboratories v. Sandoz, Inc. (N.D. Ill. 2005)

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Abbott Laboratories v. Sandoz, Inc. (N.D. Ill. 2005)

Docket   Try a Free Trial Date Filed 2005-09-16
Court District Court, N.D. Illinois Date Terminated 2010-06-24
Cause 28:2201 Injunction Assigned To Richard A. Posner
Jury Demand Defendant Referred To
Parties ABBOTT LABORATORIES; ABBOTT LABORATORIES, INC.; ABBOTT PHARMACEUTICALS PR LTD.; LORD, BISSELL & BROOK LLP; SANDOZ, INC.
Patents 4,389,393; 6,010,718; 6,068,859; 6,268,489; 6,551,616
Attorneys Alan B Clement; Andrea Weiss Jeffries; Andrew Winston Song; David B Abramowitz; Genevieve A. Cox; James T Peterka; Jason Andrew Rantanen; Jeffrey Ira Weinberger; Jennifer L. Polse; Keith D. Parr; Kevin Michael Nelson; Michael Alan Flomenhoft; Myoka Kim Goodin; R. Mark McCareins; Scott B. Feder; Ted G Dane; Todd Jay Ehlman
Firms Locke Lord Bissell and Liddell LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Abbott Laboratories v. Sandoz, Inc.
The small molecule drugs covered by the patents cited in this case are   Try a Free Trial ,   Try a Free Trial ,   Try a Free Trial , and   Try a Free Trial .

Details for Abbott Laboratories v. Sandoz, Inc. (N.D. Ill. 2005)

Date Filed Document No. Description Snippet Link To Document
2006-12-15 224 memorandum opinion and order Abbott’s U.S. Patent Nos. 6,010,718 (the “‘718 patent”), 6,551,616 (the “‘616 patent”) and 6,827,407… -1- patents. Each of these patents pertains to Abbott’s branded antibiotic…Abbott was issued two formulation patents (the ‘616 and the ‘718 patents) on an extended release formulation…upon the ‘718 patent. Id. at 1333. However, Teva raised the defense that Abbott’s ‘718 patent claims 2, …6,827,407 (the “‘407 patent”) relating to its Biaxin XL product. For purposes of this motion, however, only External link to document
2007-04-16 302 memorandum opinion and order Abbott’s U.S. Patent Nos. 6,010,718 (the “‘718 patent”), 6,551,616 (the “‘616 patent”) and 6,872,407… U.S. Pat. No. 6,010,718, at 3:53-55. “Taste profile,” a related term which the patent specifications …are substantially equal in value...”3 U.S. Patent No. 6,010,718 col.11:l.18-19 (filed Apr. 11, 1997). Abbott…conventional manner.” U.S. Pat. No. 6,010,718, at col. 3:ll. 34-39. The patent specification further states …the ‘718 patent are disclosed in the ‘571 patent, the specific PK limitations of the ‘718 patent are not External link to document
2007-05-24 352 memorandum opinion and order Abbott’s U.S. Patent Nos. 6,010,718 (the “‘718 patent”), 6,551,616 (the “‘616 patent”) and 6,872,407…718 Patent The Supreme Court recently clarified the standard for determining when a patent that…azithromycin because the ‘190 patent did not disclose the PK profile of the ‘718 patent. Sandoz repeats…Validity of Claim 6 of the ‘718 Patent and Claim 2 of the ‘616 Patent As discussed earlier, the…allegedly invalid patents or the extension of monopoly pricing by means of invalid patents over the distribution External link to document
2007-05-30 371 al. in U.S. Patent No. 4,389,393 describe sustained release therapeutic compositions…release is known. Christenson - et -al. in U.S. Patent 3,065,143 disclose the use of certain hydrophilic…preparation of sustained release tablets. Hill in U.S. Patent 3,458,622 describes the preparation of sustained… al. in U.S. Patent No. 4,252,786 describe a controlled release tablet…September 2005 24 June 2010 1:05-cv-05373 Patent Defendant District Court, N.D External link to document
2007-12-04 453 memorandum opinion and order Abbott’s U.S. Patent Nos. 6,010,718 (the “‘718 patent”), 6,551,616 (the “‘616 patent”) and 6,872,407…the ‘407 patent and Abbott has dismissed its claim that Sandoz’s infringement of the ‘616 patent was willful…alleged infringement of the ‘718 patent (as well as the ‘616 and ‘407 patents). Ranbaxy Lab. Ltd. v. Abbott…constitute infringement of a valid patent. 497 F.3d at 1371. In the area of patent infringement, a showing of…believe the ‘718 patent was invalid. Abbott is correct that case law instructs patent infringement is External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Baxter
Chinese Patent Office
Farmers Insurance
Daiichi Sankyo
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.